Suzhou Become Medical Co., Ltd. ("Become Medical") and Shenzhen Hua Dazhi Manufacturing Technology Co., Ltd. ("MGI") have reached a strategic cooperation in sequencer research and development. Become Medical’s Chairman Dr. Liang Bo, R&D Director Mr. Kong Lingyin and MGI’s President Mr. Yu Dejian attended the signing ceremony.

Both parties Committed to joint development of the next-generation automated experimental platform solutions for assisted reproduction. 

Among them, MGI, as the world's leading R&D and manufacturer of sequencers in the field of life sciences, will develop localized sequencing technology based on embryonic single-cell level sequencing: Beikang Medical will be based on the world's leading embryonic single-cell amplification SDWGA technology and the first domestic product.

The operation process of the PGT kit that has obtained the national three-class medical device registration certificate, develops the world's first embryonic single-cell level automated sequencing system, combines artificial intelligence data analysis and automatic report generation system to create an integrated next-generation automated experimental platform for assisted reproduction solution.

Beikang Medical plans to invest 430 million yuan in the field of assisted reproduction in the next 5 years to build an integrated overall experimental platform solution from detection to storage, to achieve automated gene sequencing and automated ultra-low temperature storage at the embryonic single-cell level, and complete PGT-M and PGT -SR clinical registration of two test kits, construction of a three-category medical device registration product pipeline and automated laboratory platform solutions covering the entire reproductive cycle.